PHARMANUTRA SPA (PHN.MI) Fundamental Analysis & Valuation

BIT:PHN • IT0005274094

Current stock price

74.7 EUR
-1.1 (-1.45%)
Last:

This PHN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. PHN.MI Profitability Analysis

1.1 Basic Checks

  • PHN had positive earnings in the past year.
  • In the past year PHN had a positive cash flow from operations.
  • Each year in the past 5 years PHN has been profitable.
  • PHN had a positive operating cash flow in each of the past 5 years.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • PHN has a Return On Assets of 20.17%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
  • PHN has a better Return On Equity (36.55%) than 85.71% of its industry peers.
  • The Return On Invested Capital of PHN (25.72%) is better than 100.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for PHN is significantly above the industry average of 11.83%.
  • The 3 year average ROIC (17.21%) for PHN is below the current ROIC(25.72%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROIC 25.72%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

  • PHN's Profit Margin of 13.39% is fine compared to the rest of the industry. PHN outperforms 64.29% of its industry peers.
  • PHN's Profit Margin has declined in the last couple of years.
  • The Operating Margin of PHN (21.79%) is better than 100.00% of its industry peers.
  • PHN's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of PHN (97.13%) is better than 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
Industry RankSector Rank
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PHN.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PHN is creating value.
  • PHN has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PHN has less shares outstanding
  • The debt/assets ratio for PHN has been reduced compared to a year ago.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • PHN has an Altman-Z score of 11.98. This indicates that PHN is financially healthy and has little risk of bankruptcy at the moment.
  • PHN's Altman-Z score of 11.98 is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
  • The Debt to FCF ratio of PHN is 2.01, which is a good value as it means it would take PHN, 2.01 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.01, PHN is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
  • PHN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
  • PHN's Debt to Equity ratio of 0.24 is in line compared to the rest of the industry. PHN outperforms 57.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Altman-Z 11.98
ROIC/WACC3.28
WACC7.85%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.19 indicates that PHN has no problem at all paying its short term obligations.
  • PHN's Current ratio of 2.19 is amongst the best of the industry. PHN outperforms 92.86% of its industry peers.
  • A Quick Ratio of 1.86 indicates that PHN should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.86, PHN belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.86
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. PHN.MI Growth Analysis

3.1 Past

  • PHN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.84%, which is quite good.
  • PHN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.63% yearly.
  • PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.35%.
  • PHN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.59% yearly.
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.22% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 12.06% on average over the next years. This is quite good.
EPS Next Y6.55%
EPS Next 2Y14.68%
EPS Next 3Y17.22%
EPS Next 5YN/A
Revenue Next Year15.29%
Revenue Next 2Y15.09%
Revenue Next 3Y15.07%
Revenue Next 5Y12.06%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M 250M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

1

4. PHN.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 29.76, PHN can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, PHN is valued a bit more expensive than the industry average as 71.43% of the companies are valued more cheaply.
  • The average S&P500 Price/Earnings ratio is at 24.88. PHN is around the same levels.
  • The Price/Forward Earnings ratio is 29.86, which means the current valuation is very expensive for PHN.
  • 85.71% of the companies in the same industry are cheaper than PHN, based on the Price/Forward Earnings ratio.
  • PHN is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 29.76
Fwd PE 29.86
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit more expensive than the industry average as 78.57% of the companies are valued more cheaply.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a rather expensive valuation: PHN more expensive than 85.71% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 69.37
EV/EBITDA 16.91
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHN does not grow enough to justify the current Price/Earnings ratio.
  • PHN has an outstanding profitability rating, which may justify a higher PE ratio.
  • PHN's earnings are expected to grow with 17.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.54
PEG (5Y)2.03
EPS Next 2Y14.68%
EPS Next 3Y17.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. PHN.MI Dividend Analysis

5.1 Amount

  • PHN has a Yearly Dividend Yield of 1.32%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 2.49, PHN is paying slightly less dividend.
  • PHN's Dividend Yield is slightly below the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.32%

5.2 History

  • On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • PHN pays out 39.70% of its income as dividend. This is a sustainable payout ratio.
  • PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP39.7%
EPS Next 2Y14.68%
EPS Next 3Y17.22%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PHN.MI Fundamentals: All Metrics, Ratios and Statistics

PHARMANUTRA SPA

BIT:PHN (3/27/2026, 7:00:00 PM)

74.7

-1.1 (-1.45%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)03-17
Earnings (Next)05-11
Inst Owners15.64%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap723.10M
Revenue(TTM)180.41M
Net Income(TTM)24.16M
Analysts82.86
Price Target88.74 (18.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.32%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP39.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.28%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0.43%
Revenue NY rev (3m)0.43%
Valuation
Industry RankSector Rank
PE 29.76
Fwd PE 29.86
P/S 4.01
P/FCF 69.37
P/OCF 50.04
P/B 10.94
P/tB 17.33
EV/EBITDA 16.91
EPS(TTM)2.51
EY3.36%
EPS(NY)2.5
Fwd EY3.35%
FCF(TTM)1.08
FCFY1.44%
OCF(TTM)1.49
OCFY2%
SpS18.64
BVpS6.83
TBVpS4.31
PEG (NY)4.54
PEG (5Y)2.03
Graham Number19.64
Profitability
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROCE 44.34%
ROIC 25.72%
ROICexc 34.17%
ROICexgc 53.82%
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
FCFM 5.78%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Debt/EBITDA 0.37
Cap/Depr 112.59%
Cap/Sales 2.23%
Interest Coverage 250
Cash Conversion 33.69%
Profit Quality 43.15%
Current Ratio 2.19
Quick Ratio 1.86
Altman-Z 11.98
F-Score7
WACC7.85%
ROIC/WACC3.28
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
EPS Next Y6.55%
EPS Next 2Y14.68%
EPS Next 3Y17.22%
EPS Next 5YN/A
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%
Revenue Next Year15.29%
Revenue Next 2Y15.09%
Revenue Next 3Y15.07%
Revenue Next 5Y12.06%
EBIT growth 1Y10.97%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.37%
EBIT Next 3Y20.23%
EBIT Next 5Y14.04%
FCF growth 1Y164.53%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y18.84%
OCF growth 3Y0.14%
OCF growth 5Y11.34%

PHARMANUTRA SPA / PHN.MI Fundamental Analysis FAQ

What is the fundamental rating for PHN stock?

ChartMill assigns a fundamental rating of 6 / 10 to PHN.MI.


Can you provide the valuation status for PHARMANUTRA SPA?

ChartMill assigns a valuation rating of 1 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.


What is the profitability of PHN stock?

PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.


How financially healthy is PHARMANUTRA SPA?

The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.


Is the dividend of PHARMANUTRA SPA sustainable?

The dividend rating of PHARMANUTRA SPA (PHN.MI) is 4 / 10 and the dividend payout ratio is 39.7%.